Tag: response

BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced data, comprising two posters and three abstracts, at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, demonstrating the clinical profile of dapirolizumab pegol (DZP), an investigational biologic in patients with systemic lupus erythematosus (SLE).

Funding to Propel POP BIO SNAP™ Nanoparticle Vaccine Platform into Phase 1 Clinical Trials in the U.S.

SINGAPORE, June 03, 2026 (GLOBE NEWSWIRE) -- Phaos Technology Holdings (Cayman) Limited, (NYSE: POAS), (“the Company”), an advanced microscopy solutions headquartered in Singapore, announced today that the Company had become aware of unusual trading activity in its class A ordinary shares on the New York Stock Exchange American (the "NYSE") from May 29, 2026 to June 1, 2026. The Company is issuing this updated press release pursuant to Section 401(d) of the NYSE Company Guide. The Company has made inquiries and has been unable to determine whether corrective actions are appropriate at this time. The Company is further announcing that there has been no material development in its business and affairs not previously disclosed or, to its knowledge, any other reason to account for the unusual market action.

Langenfeld, Germany, June 03, 2026 (GLOBE NEWSWIRE) -- Booking Health today announced the release of findings examining international patient access to personalized dendritic cell therapy for glioblastoma in Germany. The findings, based on a documented Canadian patient case and supporting clinical research, highlight how cross-border treatment pathways may provide patients with aggressive brain tumors access to individualized immunotherapy options that are not widely available within all healthcare systems.